Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and… Read more
Zoetis Inc (ZTS) - Total Assets
Latest total assets as of September 2025: $15.16 Billion USD
Based on the latest financial reports, Zoetis Inc (ZTS) holds total assets worth $15.16 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zoetis Inc - Total Assets Trend (2010–2024)
This chart illustrates how Zoetis Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zoetis Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Zoetis Inc's total assets of $15.16 Billion consist of 42.1% current assets and 58.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.99 Billion | 13.9% |
| Accounts Receivable | $1.32 Billion | 9.2% |
| Inventory | $2.31 Billion | 16.2% |
| Property, Plant & Equipment | $3.62 Billion | 25.4% |
| Intangible Assets | $1.13 Billion | 7.9% |
| Goodwill | $2.72 Billion | 19.1% |
Asset Composition Trend (2010–2024)
This chart illustrates how Zoetis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zoetis Inc's current assets represent 42.1% of total assets in 2024, an increase from 40.1% in 2010.
- Cash Position: Cash and equivalents constituted 13.9% of total assets in 2024, up from 1.2% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, a decrease from 34.0% in 2010.
- Asset Diversification: The largest asset category is property, plant & equipment at 25.4% of total assets.
Zoetis Inc Competitors by Total Assets
Key competitors of Zoetis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Zoetis Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Zoetis Inc generates 0.65x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Zoetis Inc generates $ 17.46 in net profit.
Zoetis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.64 | 3.69 | 3.05 |
| Quick Ratio | 2.28 | 2.27 | 2.30 |
| Cash Ratio | 0.00 | 1.00 | 0.00 |
| Working Capital | $4.78 Billion | $ 4.58 Billion | $ 4.44 Billion |
Zoetis Inc - Advanced Valuation Insights
This section examines the relationship between Zoetis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.97 |
| Latest Market Cap to Assets Ratio | 3.76 |
| Asset Growth Rate (YoY) | -0.3% |
| Total Assets | $14.24 Billion |
| Market Capitalization | $53.52 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Zoetis Inc's assets at a significant premium ( 3.76x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Zoetis Inc's assets decreased by 0.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zoetis Inc (2010–2024)
The table below shows the annual total assets of Zoetis Inc from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $14.24 Billion | -0.34% |
| 2023-12-31 | $14.29 Billion | -4.28% |
| 2022-12-31 | $14.93 Billion | +7.37% |
| 2021-12-31 | $13.90 Billion | +2.14% |
| 2020-12-31 | $13.61 Billion | +17.88% |
| 2019-12-31 | $11.54 Billion | +7.13% |
| 2018-12-31 | $10.78 Billion | +25.52% |
| 2017-12-31 | $8.59 Billion | +12.25% |
| 2016-12-31 | $7.65 Billion | -3.34% |
| 2015-12-31 | $7.91 Billion | +20.11% |
| 2014-12-31 | $6.59 Billion | +0.46% |
| 2013-12-31 | $6.56 Billion | +4.73% |
| 2012-12-31 | $6.26 Billion | +9.65% |
| 2011-12-31 | $5.71 Billion | +8.08% |
| 2010-12-31 | $5.28 Billion | -- |